Vericel (VCEL) Tops Q3 EPS by 4c, Beats on Revenue; Offers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
November 8, 2023 7:55 AM ESTRecord Third Quarter Revenue of $45.6 Million, Representing 18% Growth versus Prior Year
MACI Revenue Growth of 21% to $37.6 Million
Full-Year 2023 Revenue Guidance Raised to $192.5-197.5 Million
Conference Call Today at 8:30am Eastern Time
CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2023.
Third Quarter 2023 Financial Highlights... More
